Our data identify NF-κB as a transcriptional driver in TKI resistance, and implicate PSMD1 and PSMD3 as plausible therapeutic targets worthy of future investigation in CML and possibly other malignancies. Here, PSMD3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.